Thursday, 16 Aug 2018

You are here

ACP Guideline Recommends Generic Bisphosphonates But Limits DEXA Use

The American College of Physicians (ACP) has updated its 2008 clincial practice guideline on the treatment of low bone density and osteoporosis to prevent fractures in men and women.  The new guideline is in favor of generic bisphosphonate use and recommends against using menopausal estrogen therapy and against DEXA monitoring during the first 5 years.

Guidelines was developed using the GRADE system, based on a systematic literature review, and focuses on the comparative benefits and risks of short- and long-term pharmacologic treatments for low bone density, including pharmaceutical prescriptions, calcium, vitamin D, and estrogen.

The American College of Physicians (ACP) strongly recommends bisphosphonates (alendronate, risedronate, zoledronic acid) or denosumab for reducing fracture risk in women with osteoporosis. ACP advises physicians to prescribe generics over brand name drugs whenever possible and to discuss medication adherence with their patients, especially for bisphosphonates. 

ACP recommends against using menopausal estrogen therapy or menopausal estrogen plus progestin therapy or raloxifene for the treatment of osteoporosis in women. Estrogen treatment is associated with serious harms such as increased risk for cerebrovascular accidents and venous thromboembolic events that outweigh the potential benefits.

The evidence suggests that physicians should treat women with osteoporosis with drug therapy for five years. Continuing treatment after the initial five years may be beneficial for some patients and may be appropriate after reassessing the risks and benefits of continuing therapy.

ACP's states the evidence suggests that physicians should treat women with osteoporosis with drug therapy for 5 years. ACP recommends against bone density monitoring during the 5-year treatment period because the evidence does not show any benefit for monitoring during treatment. The evidence also does not support frequent monitoring of women with normal bone density for osteoporosis, as most women with normal bone density measurements did not progress to osteoporosis within 15 years.

Physicians should offer bisphosphonates to reduce the risk for vertebral fractures in men with known osteoporosis. The decision to treat osteopenic women 65 years of age or older who are at a high risk for fracture should be based on a discussion of patient preferences; fracture risk profile; and the benefits, harms, and costs of medications.

Osteoporosis is an enormous public health problem affecting about half of all Americans over the age of 50. The author of an editorial from Oregon Health and Science University in Portland writes that ACP’s recommendation to offer bisphosphonates or denosumab to women with osteoporosis is particularly important because, despite the wealth of evidence, osteoporosis remains underdetected and undertreated. ACP’s guideline provides a solid basis for informed clinical decision-making.

There is an accompanying video from the  ACP’s president discussing treatment of low bone density or osteoporosis are available to download at http://www.dssimon.com/MM/ACP-osteoporosis-guideline/

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Persistent Osteoporosis Drug Use Pays Off

Among elderly female Medicare patients, persistent use of osteoporosis medications was associated with reduced risk of fracture and significantly lower total health care costs.

Osteoporosis International reports the results of research examining records of 294,369 women >65 years old, on Medicare and taking osteoporosis medicines for the first time at some point between 2009 and 2011. (Citation Source: bit.ly/2vALm98) 

Fractures Augment 10 Year Mortality Risks

This nationwide study of adults (50+ yrs) from Denmark has shown that following a fragility fracture, the 10-years mortality risk was increased, especially in the first year following the fracture. 

Early Hip Fracture Surgery Reduces Mortality

CMAJ reports that seniors are more likely to survive a hip fracture if the surgery is done as soon as they’re admitted to the hospital - suggesting hospitals should expedite operating room access for patients whose surgery has already been delayed for nonmedical reasons. (Citation source: bit.ly/2KzdrCt) 

Big Advances for Two Osteoporosis Drugs

New developments with the FDA and new scientific findings are adding momentum to two drugs experts believe are game-changers in osteoporosis treatment.

In May, the FDA approved denosumab (Prolia) for use in patients who have glucocorticoid-induced osteoporosis and are at high risk of fracture. 

Update on Osteoporosis

This session was an update on the management of osteoporosis given by Professor Christian Roux from France.

He emphasised the use of composite risk score like the FRAX. He highlighted that the risk of vertebral fracture is increased by both the recency and severity of previous vertebral fracture. So it is important that those with vertebral fractures are followed up and treated appropriately to prevent subsequent fractures.